Analysts think CLSD stock price could increase by 540%
Apr 07, 2025, 11:25 AM
-3.77%
What does CLSD do
Clearside Biomedical, headquartered in Alpharetta, Georgia, specializes in therapies delivered to the eye via the suprachoroidal space and has developed the approved product XIPERE. The company’s lead program, CLS-AX, is in Phase 2b clinical testing for wet AMD.
8 analysts think CLSD stock price will increase by 540.34%. The current median analyst target is $5.61 compared to a current stock price of $0.88. The lowest analysts target is $4.04 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
